Do anti‐IL‐6R blockers have a beneficial effect in the treatment of antibody‐mediated rejection resistant to standard therapy after kidney transplantation?

Antibody‐mediated rejection (AMR) that resists to standard of care (SOC) therapy remains a major challenge after kidney transplantation and leads to graft failure in a majority of cases. The use of anti‐IL6 receptor antibodies was suggested to treat chronic antibody‐mediated rejection (cAMR) after f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of transplantation 2021-04, Vol.21 (4), p.1641-1649
Hauptverfasser:	Massat, Maéva, Congy‐Jolivet, Nicolas, Hebral, Anne‐Laure, Esposito, Laure, Marion, Olivier, Delas, Audrey, Colombat, Magali, Faguer, Stanislas, Kamar, Nassim, Del Bello, Arnaud
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Apheresis Case reports clinical research / practice Graft rejection Graft Rejection - drug therapy Graft Rejection - prevention & control Graft Survival Grafts Human health and pathology Humans Immunoglobulins Immunoglobulins, Intravenous - therapeutic use immunosuppressant ‐ other immunosuppression / immune modulation Immunotherapy Infectious diseases Inflammation Interleukin 6 Intravenous administration Isoantibodies Kidney transplantation Kidney Transplantation - adverse effects kidney transplantation / nephrology Kidney transplants Life Sciences Monoclonal antibodies pathology / histopathology Patients rejection: antibody‐mediated (ABMR) rejection: chronic Renal function Rituximab Standard of Care
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!